Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CEPH -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (760)	5/14/1998 3:19:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 998

VLAD: I've collaborated with FDA scientists and taken projects to them for conceptual discussions that led to clinical testing. I don't see it your way. The data was inconsistent, and FDA has a responsibility to require a clear demonstration of efficacy. IMO, they're trying to do their job, not punish anyone. I wish everyone would get off their case and help them to use their resources optimally. Public sentiment can't cover up the deficiencies in the Cephalon/Chiron argument. I also hope that Myotrophin wins approval. I'd like to see the ALS patient population get the right to run the patient-by-patient experiments (combined therapy) that they want to conduct. We need, however, a regulatory agency that doesn't let "placebo-equivalents" through to approval. FDA is walking a tough line, and we should be as understanding of their responsibilities as we are compassionate to ALS patients. There are companies out there that are trying to shove crud through the approval process. Rick